Objective: To test the effects of doxazosin, an α1 antagonist, on cognitive functioning during tobacco withdrawal in smokers.
| INTRODUCTION
Noradrenergic pathways in the prefrontal cortex play a critical role in supporting higher order cognitive functions (Berridge & Spencer, 2016) . There are three classes of noradrenergic receptors, namely, α1, α2, and β receptors. A sizeable body of work has explored the effects of drugs targeting α2 and β on cognitive performance in humans (Greenblatt, Scavone, Harmatz, Engelhardt, & Shader, 1993; Jakala et al., 1999) ; however, less is known about potential cognitive effects of drugs that target α1 receptors. Preclinical studies indicate that α1 receptors are selectively engaged when high concentrations of norepinephrine are released (e.g., stress and withdrawal), and activation of α1 receptors impairs cognitive performance (Ramos & Arnsten, 2007) . Administration of an α1 antagonist blocked any disruptive effects of stress on cognitive performance in rats, suggesting that therapeutic action at α1 may be beneficial to cognitive functioning (Birnbaum, Gobeske, Auerbach, Taylor, & Arnsten, 1999) . Other preclinical studies have examined which aspects of cognitive performance are affected by α1 signaling, finding that activation of α1 receptors is associated with impairment of some cognitive functions (e.g., working memory) but may improve others (e.g., sustained attention; Berridge & Spencer, 2016) .
These preclinical findings highlight a complex role for α1 receptors in cognition, and less is known about the cognitive effects of drugs targeting α1 receptors in humans. One study found that prazosin, a short duration α1 antagonist, can improve cognitive performance in healthy human participants (Winder-Rhodes et al., 2010) .
Such cognitive enhancing effects of α1 antagonists may explain why these drugs can reduce rates of substance use. Indeed, several clinical trials along these lines have already been conducted for substance use disorders. Doxazosin was effective at reducing cocaine use in those with cocaine use disorder (Shorter, Lindsay, & Kosten, 2013) , and prazosin reduced both cue-induced craving and alcohol consumption among groups of patients with alcohol use disorder (Fox et al., 2012) .
That α1 antagonists can improve cognitive functioning suggests that these drugs may have efficacy as smoking cessation aids. Current Food and Drug Administration-approved medications aid smokers attempting to quit by reducing withdrawal symptoms and blocking tobacco-related reinforcement (Ashare & Schmidt, 2014) . Even with these smoking cessation medications, the majority of smokers attempting to quit are unsuccessful in the long term (Fiore et al., 2008) , highlighting the importance of developing more effective treatments for smoking. Recent work has identified withdrawal-related cognitive deficits as a pharmacological target for tobacco use disorder (Ashare & Schmidt, 2014) . Smokers attempting to quit who show cognitive impairment during withdrawal are at increased risk for relapse (Patterson et al., 2010) , likely because they must rely on executive cognitive functions to maintain abstinence as they experience cravings and other symptoms of withdrawal.
This manuscript reports data taken from a larger preliminary human laboratory study (Verplaetse et al., 2017) screening doxazosin (placebo, 4 mg/day, and 8 mg/day) as a treatment for tobacco use disorder in a group of non-treatment-seeking daily smokers. The current study was the first to examine the effects of an α1 antagonist on cognitive performance during tobacco withdrawal in humans. A continuous performance task (CPT; Conners, 2000) was used to measure different aspects of cognitive performance, including inhibitory control (commission errors), sustained attention (reaction time variability
[RTvar]), and reaction time (RTgo). Participants completed the CPT during three separate sessions. First, they completed a medicationfree baseline assessment. Following a medication titration period, they completed the CPT and self-reported symptoms of tobacco withdrawal during separate tobacco-deprived and non-tobacco-deprived laboratory sessions. During the deprivation session, participants also completed a smoking lapse task to measure their ability to resist the urge to smoke following a period of tobacco deprivation (McKee, 2009) .
For the present set of analyses, we hypothesized that doxazosin would improve performance on the CPT as evidenced by improvement from baseline to the nondeprived session. We predicted that participants would perform worse on all measures on the CPT during tobacco deprivation compared with their baseline assessment. However, we hypothesized that participants receiving doxazosin would show less impairment when tobacco deprived than those receiving placebo. We also predicted that participants receiving doxazosin would report fewer withdrawal symptoms during tobacco deprivation than those on placebo. We hypothesized that individual differences in doxazosin effects on cognitive functioning and withdrawal would be associated with smoking behavior on the smoking lapse task. Finally, we hypothesized that self-reported withdrawal symptoms would be associated with cognitive impairment during deprivation. This prediction was based on research suggesting that cognitive impairment is a core symptom of tobacco withdrawal that should be expected to covary with the intensity of the broader withdrawal syndrome (Ashare, Falcone, & Lerman, 2014) .
| METHOD

| Participants
Eligible participants were non-treatment-seeking adult smokers (18-60 years old) who smoked ≥10 cigarettes per day for the past year, had baseline carbon monoxide (CO) levels ≥10 ppm, had urine cotinine levels ≥150 ng/ml, and were normotensive with normal electrocardiograms. Participants were excluded for medical conditions that contraindicated smoking or doxazosin use, other DSM-IV Axis I diagnosis except alcohol abuse or tobacco dependence, and illicit drug use except occasional marijuana use. Thirty-five individuals (4-mg/ day doxazosin, n = 11; 8-mg/day doxazosin, n = 13; placebo, n = 11) enrolled in and completed the study. As seen in Table 1 , groups were well matched on most baseline variables, although there were significant group differences in Fagerstrom test of nicotine dependence (FTND) scores (Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) . The study was approved by the Yale Human Investigations Committee. All participants provided written informed consent and were compensated for participation. Additional participant details are reported in the parent publication (Verplaetse et al., 2017) .
| Study design
This experiment used a double-blind and placebo-controlled design to examine the effects of doxazosin on cognitive functioning and tobacco withdrawal. Doxazosin was administered once daily and titrated to steady-state levels over 18 days (for 4-mg/day doxazosin: 1 mg daily for Days 1-4, 2 mg daily for Days 5-9, 4 mg daily on and after Day 10; for 8-mg/day doxazosin 1 mg daily for Days 1-4, 2 mg daily for Days 5-9, 5 mg daily for Days 10-13, 6 mg daily for Days 14-17, 8 mg daily on and after Day 18). Placebos were matched in appearance and were taken on the same schedule as the active medication. Medication compliance was monitored by pill counts and riboflavin marker. Following completion of the laboratory sessions, participants were tapered from medication over a 4-day period. Participants attended a premedication baseline assessment session and two laboratory testing sessions, including a nondeprivation session and a deprivation session. Adverse event and other methodological details not pertinent to the current report are described in the parent publication (Verplaetse et al., 2017) .
| Material and measures
| Conners' CPT
The CPT is a computerized assessment tool that measures cognitive performance (Conners, 2000) . Participants viewed a series of letters on a computer monitor for 14 min. They were instructed to respond as quickly as possible to target stimuli (all letters but "X") and to refrain from responding to the infrequent nontarget stimuli (X). Criterion variables were the percentage of nontarget (X) trials that participants made a response (% commission errors), RTgo, and RTvar. Omission errors occurred infrequently (< 5% of trials) and are not reported.
| Smoking lapse task
The smoking lapse task is a validated model of smoking relapse (McKee, Krishnan-Sarin, Shi, Mase, & O'Malley, 2006) . Prior to completing the smoking lapse task, participants were exposed to neutral imagery using personalized guided imagery in order to induce a neutral mood (McKee et al., 2011) . This mood induction was included as part of a larger manipulation described in the parent study. The smoking lapse task consists of two phases. During the delay phase, participants were presented with a tray containing eight cigarettes of their preferred brand, a lighter, and an ashtray. They were told that they could commence smoking at any point during the next 50 min; however, for each 5 min that they delayed smoking, they would earn US $1 for a maximum of US $10 during the delay period. They were informed that the delay session would end after 1 hr regardless of whether they chose to smoke. The second phase was a free-access period that started after participants decided to end the delay phase by smoking or waiting for 50 min. Participants were provided with eight cigarettes of their preferred brand.
Criterion variables included smoking delay (i.e., time between the beginning of the delay phase and the participant choosing to smoke); smoking latency (i.e., time between the beginning of the free-access smoking phase and the participant taking his or her first puff); and total cigarettes (i.e., number of cigarettes smoked during the freeaccess phase).
| Minnesota Nicotine Withdrawal Scale (Hughes & Hatsukami, 1986)
The Minnesota Nicotine Withdrawal Scale (MNWS) is an eight-item questionnaire used to assess current withdrawal symptoms. Participants rate the intensity of their current symptoms (e.g., anxiety, difficulty concentrating, and craving for cigarettes) on a 5-point scale ranging from 0 (none) to 4 (severe) with scores ranging from 0 to 32.
| Procedure
| Premedication baseline assessment
This baseline assessment session began at 9:00 am on Day 1, and participants were instructed not to smoke after 10:00 pm on the previous night. Abstinence was confirmed with a CO reading. Baseline assessments of breath CO and breath alcohol were conducted, a urine sample was collected for drug and pregnancy screening, and past-month self-reported smoking was assessed. Participants were given cigarette breaks as needed after biological specimens were collected. They completed the CPT within 1 hr of smoking to ensure that the baseline cognitive assessment was completed in a satiated state.
| Laboratory sessions
Participants attended two laboratory sessions including a nondeprivation and tobacco-deprived laboratory session.
Nondeprivation session
The nondeprivation session occurred between 17 and 21 days following the premedication baseline assessment. This session began between 9:00 am and 2:00 pm and required approximately 3 hr to complete. Although participants were instructed to remain abstinent for at least 11 hr preceding the session, they were allowed to take smoke breaks as needed after providing urine and blood samples.
They completed the CPT within 1 hr of smoking a cigarette.
Deprivation session
Participants attended a second laboratory session where they completed the same procedures in a tobacco-deprived state. This session occurred approximately 24 days (with allowance for variability based on participants' schedules) following the premedication baseline assessment. Participants were instructed to abstain from smoking for at least 11 hr preceding the session, and they were not allowed to smoke until the free-access period of the smoking lapse task. The session began at 8:00 am. Smoking abstinence was biochemically confirmed with CO readings (less than 50% of their CO level at intake; Kahler et al., 2012) and later with serum nicotine levels (less than 2 ng/ml). Participants completed the CPT at 9:15 am. They began the smoking delay period at 1:10 pm. 
| Statistical analyses
Performance data from the CPT were analyzed using a 3 dose (placebo, 4 mg/day, and 8 mg/day) × 3 session (baseline session, nondeprivation session, and deprivation session) mixed-design analysis of variance (ANOVA). A 2 session (non-deprived versus deprived) × 3 (dose)
mixed-design analysis of covariance (ANCOVA) that included MNWS score during baseline assessment as a covariate was used to examine the effects of medication on withdrawal symptoms. FTND scores also were included as a covariate but did not change the pattern of results.
Final models are presented without FTND scores included as a covariate.
Any significant interaction was probed using one-tailed a priori t tests comparing each session to baseline within each dose. Because the study was preliminary, one-tailed tests were used to reduce the risk of Type II error. We expected that performance during the nondeprivation session would improve compared with baseline and performance during the deprivation session was expected to decline compared with baseline (comparison was between nondeprived and deprived laboratory sessions for MNWS scores). When these ANOVAs or ANCOVAs identified a significant main effect of session but no significant interaction, we collapsed across medication conditions and used a priori t tests to compare performance during tobacco deprivation with baseline performance. Similar a priori t tests on MNWS scores were used to detect any increases in scores during the deprivation session relative to the nondeprivation session. Correlation analyses were used to test whether MNWS scores during the deprivation session were associated with changes in cognitive performance during that same session.
A second set of analyses tested whether any medication-related changes in withdrawal symptoms or cognitive functioning were associated with smoking behavior on the smoking lapse task. Medication effect scores were calculated as the difference in performance between the baseline and nondeprivation medication session and deprivation scores as the difference between the baseline session and deprivation session. We only calculated these scores on CPT variables that showed a significant session × medication interaction effect to reduce the number of comparisons being made. Correlational analyses determined whether medication-induced changes in cognitive functioning were associated with criterion variables from the smoking lapse task. For these analyses, we collapsed the 4-and 8-mg/day doxazosin groups and conducted correlational analyses separately for those receiving active medication and those receiving placebo. A similar set of analyses was conducted to test the relation between withdrawal symptoms during deprivation and smoking behavior.
Withdrawal was defined as the difference between MNWS scores at baseline and during the deprivation session. Further examination of Figure 1 shows that, contrary to our hypothesis, participants receiving 8-mg/day doxazosin made fewer commission errors during the tobacco-deprivation session compared with premedication baseline. Our initial analytic strategy did not allow us to test the significance of this reduction, so an exploratory t test was conducted to confirm that this improvement was significant, t (12) = 2.10, p = .03, suggesting that participants receiving 8-mg/day doxazosin retained their improvements of inhibitory control compared with premedication baseline even when tobacco deprived.
| Reaction time to go targets
Two participants were identified as outliers (RTgo > 600 ms) and removed from analyses of RTgo and RTvar. RTgo is charted in Figure S1 . There was no main effect of medication, F(2, 28) = 0.02, p = .98, or medication × session interaction, F(4, 56) = 0.63, p = .65.
The main effect of session was significant, F(2, 56) = 10.20, p < .01.
Because there was no significant interaction effect, we collapsed across medication groups for our a priori tests of session effects. RTgo was no faster during the nondeprivation session compared with the premedication baseline assessment, t (32) = 0.21, p = .42. They did, however, show slower RTgo during the deprivation session compared with their premedication baseline, t (32) = 3.62, p < .01. Non-tobacco-deprived sessions were conducted within 1 hr of smoking. Tobacco-deprived sessions were conducted following at least 11 hr of abstinence. Symbol above bar shows significant difference from premedication baseline, *p < .05. DOX = active doxazosin conditions
| Reaction time variability
RTvar is plotted in Figure S2 . There was a significant main effect of session, F(2, 56) = 4.01, p = .02. The main effect of medication was not significant, F(2, 28) = 0.24, p = .79, nor was the session × medication interaction, F(4, 56) = 0.78, p = .55. We collapsed across medication group and used a priori t tests to probe the main effect of session.
RTvar was not reduced during the nondeprivation session compared with the premedication baseline assessment, t (32) = 0.86, p = .24.
During the deprivation session, RTvar increased compared with the medication-free baseline assessment, t (32) = 3.28, p = .01.
| Self-reported withdrawal symptoms
MNWS scores are reported in Figure 2 
| Medication and deprivation effects predicting smoking behavior.
Among participants receiving active medication, the average reduction in percentage commission errors during the steady-state medication assessment was 2.65% (SD = 16.13%). The average reduction during the deprivation session was 2.29% (SD = 13.46). In the placebo group, there was little change from the baseline assessment to the nondeprivation session (M change = 0.04%, SD = 8.93%). The average increase in percentage commission errors during the deprivation session was 9.83% (SD = 12.13%).
The relation between medication and deprivation effects on commission errors on the CPT and smoking variables is reported in Table 2 .
There were no significant relations among smoking variables and medication or deprivation effects in the placebo group. In the active medication conditions, however, participants who showed the largest improvement on commission errors also delayed smoking the longest.
| MNWS scores during deprivation predicting smoking behavior
Compared with baseline, scores on the MNWS during the deprivation session increased by 4.36 (SD = 4.84) in the placebo group and 1.71
(SD = 5.63) in the active medication groups. Relations among deprivation-induced increases in withdrawal symptoms and smoking behavior are described in Table 1 . In the active medication group, those who reported the largest increase in withdrawal symptoms during deprivation had the briefest delay to smoking during both phases of the smoking lapse task (i.e., smoking delay and latency) and smoked more cigarettes during the free-access phase. This relation is illustrated in Figure 3 . Participants who received active doxazosin self-reported fewer withdrawal symptoms during tobacco deprivation, and having fewer withdrawal symptoms was associated in turn with smoking fewer cigarettes when given ad libitum access.
| Medication effects on smoking behavior
There were no significant treatment emergent symptoms reported by participants in this study. Direct effects of medication condition on smoking behavior are reported in the primary manuscript from the parent study (Verplaetse et al., 2017) .
| DISCUSSION
This study tested the effects of doxazosin on smokers' cognitive func- In addition to demonstrating doxazosin's ability to attenuate some aspects of cognitive impairment during withdrawal, we also found that the drug reduced self-reported withdrawal symptoms per the MNWS.
This effect was most evident among participants receiving 4-mg/day doxazosin-those receiving 8 mg/day reported an increase in withdrawal symptoms during deprivation. As reported in the parent study and in prior investigations (Stoschitzky et al., 2003; Verplaetse et al., 2017) , doxazosin increases heart rate, suggesting that the drug may paradoxically have sympathomimetic effects under certain circumstances. These effects may have strengthened at higher doses, potentially offsetting the beneficial effects of the drug on withdrawal symptoms. Another possibility relates to the U-shaped association between noradrenergic tone and stress response (Arnsten, 2009 ).
The 8-mg/day doxazosin dose may have altered noradrenergic tone below optimal levels, effectively increasing susceptibility to stressors such as tobacco withdrawal. Additional research will be necessary to determine the mechanisms by which noradrenergic medications can attenuate tobacco withdrawal and to better characterize the doseresponse curve. The lack of association between self-reported withdrawal symptoms and behavioral disinhibition among those receiving active medication suggests that doxazosin attenuated the expression of disinhibition as a symptom within the broader tobacco withdrawal syndrome (Shiffman et al., 1995) .
Participants receiving active doxazosin reported fewer withdrawal symptoms; those with fewer withdrawal symptoms could resist smoking for longer and smoked less when given free access to cigarettes. This finding is consistent with prior preclinical research demonstrating that prazosin administered during tobacco withdrawal attenuated the withdrawal-induced reduction in brain reward threshold, which may explain its effects on withdrawal symptoms (Bruijnzeel et al., 2010) . Although some extant smoking cessation medications block withdrawal symptoms by acting as nicotinic acetylcholine receptor (nAChR) agonists, this strategy can lead to increased expression of nAChR, which may prolong withdrawal (Hussmann et al., 2012) .
Doxazosin may reduce withdrawal-related symptoms without targeting nAChRs, potentially allowing for quicker downregulation of these receptors while providing relief from withdrawal.
This study was among the first to examine the effects of an α1 antagonist on cognitive functioning in humans and provides insight into the role of α1 receptors in cognitive functioning. Prior research in humans found that the α2 agonist guanfacine can improve inhibitory control (Fox, Sofuoglu, & Sinha, 2015) , suggesting that increasing activity at presynaptic α2 receptors can improve cognitive functioning, likely by reducing synaptic concentrations of norepinephrine (Arnsten, 2011) . Results of the current study suggests that α1 antagonism also can improve inhibitory control, presumably through a similar mechanism. A future direction for this line of work may be examining gender differences in responses to noradrenergic medications such a doxazosin, because drugs targeting the noradrenergic system may 
FIGURE 3
Relation between degree of increase in Minnesota withdrawal scale score during deprivation session relative to baseline and number of cigarettes smoked during the free-access phase of the smoking lapse task. Dashed line is least-squares linear regression line for combined sample. The association is significant at p < .05. DOX = active doxazosin conditions attenuate smoking through gender-specific mechanisms (i.e., stress reactivity in women and tobacco reinforcement in men; Verplaetse et al., 2015) .
These findings identify a potential mechanism by which doxazosin improves outcomes across several psychiatric and neurological conditions. Rationale for prior clinical trials using noradrenergic drugs to reduce substance use has focused on its ability to block stress responses to minimize stress-induced relapse (Kenna et al., 2016; Verplaetse et al., 2015) or block drug reinforcment (Drouin et al., 2002; Ventura, Morrone, & Puglisi-Allegra, 2007) . However, we found that doxazosin may enhance inhibitory control beyond medicationfree baseline levels, which may explain its ameliorative effects on a range of disorders characterized by behavioral disinhibition (e.g., alcohol and cocaine use disorder; Kenna et al., 2016; Shorter et al., 2013) .
This study provides important information regarding the cognitive effects of an α1 adrenergic antagonist in daily smokers; however, these findings should be interpreted in light of some limitations. First, this was a small preliminary study. Analyses were intended to be hypothesis generating. The sample size was underpowered to detect small or medium effects, particularly for correlation analyses related to the smoking lapse task. Only one of the critical correlations involving task performance was significant. It will be important to replicate these findings in a larger sample. Second, participants in this study were not seeking treatment to reduce tobacco use. Although the smoking lapse task models motivation to remain abstinent by compensating participants for resisting smoking, it is possible that treatment seekers may be more motivated to use their improved inhibitory control to avoid smoking.
Finally, the order of the deprived and nondeprived laboratory sessions was not counterbalanced. It is possible that order effects may have influenced our findings.
| CONCLUSION
In conclusion, doxazosin improved inhibitory control in smokers and may reduce withdrawal symptoms during tobacco deprivation. This research identifies a potential pathway by which doxazosin might improve outcomes for smokers as well as people with other disorders characterized by cognitive impairment. Additional research will be necessary to replicate and extend these findings.
